跳至主要内容
临床试验/CTRI/2019/10/021760
CTRI/2019/10/021760进行中(未招募)4 期

A long-term non-interventional observational study in Living Donor Liver Transplant Recipients (LDLTRs) with primary hepatocellular carcinoma (HCC) treated with Certican® / Zortress® (everolimus; EVR) plus reduced tacrolimus (rTAC) versus standard tacrolimus (sTAC) control

ovartis Healthcare Pvt Ltd0 个研究点目标入组 1 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
进行中(未招募)
发起方
入组人数
1

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. Patients who have completed 24 month RCT study CRAD001H2307 and had primary HCC at the time of liver transplantation.
  • 2. Patient who signed the informed consent to participate in this NIS.

排除标准

  • 1. Patient with a liver graft loss during the 2 years in the CRAD001H2307 study.

研究者

发起方
ovartis Healthcare Pvt Ltd

相似试验